Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levofloxacin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 7/20 | 1.00 |
| ▸ | TUBB | P07437 | 7/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 7/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 7/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 7/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 7/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 7/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 7/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ofloxacin SCHEMBL6090650 | 1.00 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL6092282 | 1.00 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Levofloxacin Anhydrous SCHEMBL891190 | 1.00 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Levofloxacin Anhydrous SCHEMBL30009030 | 1.00 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Levofloxacin Anhydrous SCHEMBL27810870 | 0.99 | KDM4E (0.98) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL9745243 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Dextrofloxacine SCHEMBL4316947 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL14163982 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL5532921 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL24373 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119970632-A | Levofloxacin sodium chloride injection and preparation method thereof | 重庆药谷制药有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-117601700-B | Energy flow management method, device and system of charging station | 深圳市优优绿能股份有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-114432258-A | Levofloxacin tablet and preparation method thereof | 浙江普利药业有限公司 | 2022-05-06 | — | — | CN | claimed |
| US-9925141-B2 | Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders | CMPD LICENSING LLC (US) | 2018-03-27 | — | — | US | claimed |
| US-20170027865-A1 | Dry Pharmaceutical Compositions for Topical Delivery of Oral Medications, Nasal Delivery and to Treat Ear Disorders | CMPD LICENSING LLC (US) | 2017-02-02 | — | — | US | claimed |
| US-20150313836-A1 | Dry Pharmaceutical Compositions for Topical Delivery of Oral Medications, Nasal Delivery and to Treat Ear Disorders | CMPD LICENSING LLC (US) | 2015-11-05 | — | — | US | claimed |
| WO-2014204718-A1 | DRY PHARMACEUTICAL COMPOSITIONS FOR TOPICAL DELIVERY OF ORAL MEDICATIONS, NASAL DELIVERY AND TO TREAT EAR DISORDERS | CMPD LICENSING, LLC (US) | 2014-12-24 | — | — | WO | claimed |
| US-20140371134-A1 | Dry Pharmaceutical Compositions for Topical Delivery of Oral Medications, Nasal Delivery and to Treat Ear | CMPD LICENSING, LLC | 2014-12-18 | — | — | US | claimed |
| CN-101781314-B | Preparation process of levofloxacin hemihydrate | ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD | 2012-03-14 | — | — | CN | claimed |
| CN-101781314-A | Preparation process of levofloxacin hemihydrate | SHANGYU JINGXIN PHARMACEUTICAL | 2010-07-21 | — | — | CN | claimed |
| EP-1451194-A4 | PREPARATION OF LEVOFLOXACIN AND FORMS THEREOF | TEVA PHARMA (IL) | 2005-06-22 | — | — | EP | claimed |
| US-20050124629-A1 | Methods for the purification of levofloxacin | ENTIRE INTEREST | 2005-06-09 | — | — | US | claimed |
| EP-1460997-A2 | METHODS FOR THE PURIFICATION OF LEVOFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-09-29 | — | — | EP | claimed |
| EP-1451194-A2 | PREPARATION OF LEVOFLOXACIN AND FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-09-01 | — | — | EP | claimed |
| WO-2004055025-A1 | PURE LEVOFLOXACIN HEMIHYDRATE AND PROCESSES FOR PREPARATION THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2004-07-01 | — | — | WO | claimed |
| US-20030144511-A1 | Methods for the purification of levofloxacin | TEVA PHARMACEUTICAL USA, INC. | 2003-07-31 | — | — | US | claimed |
| US-20030130507-A1 | Preparation of levofloxacin and forms thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-07-10 | — | — | US | claimed |
| WO-2003045329-A2 | METHODS FOR THE PURIFICATION OF LEVOFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-06-05 | — | — | WO | claimed |
| WO-2003028665-A2 | METHODS FOR THE PURIFICATION OF LEVOFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-04-10 | — | — | WO | claimed |
| WO-2003028664-A2 | PREPARATION OF LEVOFLOXACIN AND FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-04-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144511-A1 | Methods for the purification of levofloxacin | PRDX5, PRDX6, PRDX1 | KDM4E 2852/4885TUBB4A 1034/4885TUBB 918/4885 |
| US-20030130507-A1 | Preparation of levofloxacin and forms thereof | CYP2F1, CYP4F11, CYP4F2 | KDM4E 1272/4885TUBB4A 2068/4885TUBB 1586/4885 |
| US-20050124629-A1 | Methods for the purification of levofloxacin | PRDX5, PRDX6, PRDX1 | KDM4E 2852/4885TUBB4A 1034/4885TUBB 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.